Sitemap - 2025 - Big Pharma Sharma
ASH 2025: Is This the Beginning of the End for Autologous CAR-T in Multiple Myeloma?
Drug Dealin Ep. 7: Biotech M&A Insights
Is Cell Therapy "Out of Favor" or Undervalued?
Caribou Whispers Parity with Vispa-Cel. But Can Anyone Hear Them?
GenMab's Halloween Costume and NK stands for 'Not Keeping' at Takeda
Pfizer Acquires a GLP-1 Pipeline and Revives FOMO Corporate Strategy
Drug Dealin' Podcast | Ep. 6: Should the FDA Be Independent?
The In Vivo Gold Rush: Big Pharma's $3B Cell Therapy Bet
Moderna's Oncology Inflection Point: When Platform Dreams Meet Strategic Reality
Changing of the Guard at AbbVie: New Leadership = New Strategy
Drug Dealin' Ep. 5: How to Talk to Doctors | Feat. Joe McCann, Co-Founder/CEO of Slingshot Insights
ASCO 2025: Bicara vs. Merus in a Set-to-Change Head & Neck Cancer Treatment Paradigm
ASCO25: Ivonescimab Dis-HARMONi, is it a Rabbit or a Duck?
Drug Dealin' Ep.4: Ozempic for the Brain, A New Era to Explain
Vinay Prasad at CBER: What His Appointment Signals for the Future of Biotech Regulation
What 2025 Holds for GLP-1s in Brain Health
Biotech Czar for a Day: An Abundance Agenda for Biotech
Drug Dealin' Ep. 3: Rise of the Phoenix | Sujal Shah & CymaBay Therapeutics
The Unraveling of Hims’ GLP-1 Strategy
A Crucial Moment in IPF: What Boehringer Got Right, Why Roche Walked, and What’s Next
Drug Dealin' Ep. 2: Predictions for Biopharma in 2025
Drug Dealin' Ep. 1: Do Pharma companies avoid cures?
Drug Dealin' Ep. 0: Welcome to the Drug Dealin' Podcast!